Panel to finalise cancer drugs for 30% trade margin cap; Rs 2,500 crore annual savings possible

An expert group is finalizing the list of cancer medicines for a new trade margin cap. The government plans to implement a 30% cap to reduce drug prices and save patients money. Retail prices of some anti-cancer drugs could drop by up to 70% as a result of this cap. The trade margin rationalisation will apply to all cancer medicines, including branded and generic versions.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/WohERwL
via IFTTT

Read More

Supreme Court questions govt over drug pricing, asks why cap limited to anti-cancer medicines

The Supreme Court expressed its worry over the government's restriction of price control measures to only anti-cancer drugs, questioning why other vital medications lack similar oversight when sold at exorbitant rates. The Solicitor General emphasized the importance of maintaining a balance between drug availability and market dynamics in determining prices.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Luz1p5H
via IFTTT

Read More

Joint pain isn’t the same for everyone. Should treatment be?

Joint pain is frequently dismissed as an inevitable consequence of aging; however, it may point to significant underlying issues. Symptoms like stiffness and inflammation warrant a consultation with healthcare professionals. Various forms of arthritis necessitate unique treatment approaches, and symptoms can differ from person to person. Maintaining an active lifestyle and a healthy weight is crucial for preserving joint health.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/KfBZET3
via IFTTT

Read More

Roche calls for global healthcare overhaul to tackle disease burden

Roche highlights the urgent need for a transformation in global healthcare to effectively tackle chronic diseases. Jorg Rupp pointed out that existing healthcare infrastructures are largely reactive, falling short in proactively addressing the rise of non-communicable diseases. This burgeoning issue not only challenges health systems but also imposes heavy financial demands. Governments must begin viewing healthcare as a crucial investment aimed at enhancing health outcomes.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/BQphSg0
via IFTTT

Read More

Tricog Health targets 100 million cardiac screenings by 2030: CEO Dr Charit Bhograj

Bengaluru-based Tricog Health aims to conduct 100 million cardiac screenings by 2030, having screened over 41 million patients since its founding in 2014. The healthtech firm uses AI-enabled ECG devices and specialist reviews to detect heart conditions, with operations across several Indian states and 14 countries. Its technology aims to reduce diagnosis delays and improve early detection of cardiovascular diseases.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/fBrLahj
via IFTTT

Read More

Indian pharma's risk aversion holding back innovation: Kiran Mazumdar-Shaw

Biocon chairperson Kiran Mazumdar-Shaw calls for greater use of digital technology to speed up drug development, as industry leaders push for a shift beyond generics.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/1Sm9YKA
via IFTTT

Read More

Health ministry proposes curbs on prescription drug ads by retailers, wholesalers and distributors

The union health ministry has proposed extending advertising restrictions on prescription drugs to retailers and distributors. This change will bar them from advertising certain medicines without prior government approval. The amendment affects drugs covered under Schedules H, H1, and X, which require medical oversight. The existing regulations already apply to pharmaceutical manufacturers. The recommendation for this amendment comes from the Drugs Technical Advisory Board.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/FKdI3EX
via IFTTT

Read More